Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

B2B sales

- PMLiVE

Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer

The combination therapy has been authorised for use in adults harbouring KRAS G12C mutations

- PMLiVE

ICR researchers uncover genes responsible for tumour progression in prostate cancer

The findings could pave the way for new treatment approaches that improve patient outcomes

- PMLiVE

AstraZeneca’s Calquence granted FDA approval in untreated mantle cell lymphoma

More than 27,500 people worldwide are affected by the rare form of non-Hodgkin lymphoma

- PMLiVE

PM Society Awards 2025 – tickets now on sale

This year's Awards will take place on Friday 14 March at JW Marriott Grosvenor House in London

Defining the “Why” in Virtual Team Settings – Building Company Culture Virtually

Defining your team's purpose in a virtual setting is crucial for success. Are your workflows clear and documentation accessible? Learn how these elements can transform team dynamics and boost productivity,...

Impetus Digital

- PMLiVE

Uniphar appoints industry leader, Isaac Batley, as Global Head of Scientific Communications

Isaac Batley, an experienced CEO with 35 years’ experience within healthcare and pharmaceutical communications, joins Uniphar to spearhead its medical communications division.

Uniphar

- PMLiVE

Eli Lilly’s Omvoh granted FDA approval to treat Crohn’s disease in adults

The drug is already approved in the US to treat ulcerative colitis, another form of inflammatory bowel disease

- PMLiVE

Novo Nordisk and Valo Health expand alliance for cardiometabolic diseases

The partners are aiming to develop new drugs for type 2 diabetes, obesity and cardiovascular disease

- PMLiVE

Santhera’s Duchenne muscular dystrophy drug Agamree accepted by SMC

The rare muscle-wasting disorder affects approximately 2,500 males in the UK at any one time

- PMLiVE

What’s next for scientific congress booths: five trends for 2025

By Lauren Vosseller and Alison Dufour

Amiculum

- PMLiVE

AbbVie and Simcere to advance multiple myeloma candidate in partnership worth over $1bn

SIM0500 is in phase 1 development for patients with relapsed or refractory cases of the blood cancer

Biogen Idec building

Biogen/Eisai announce FDA BLA acceptance for injectable Alzheimer’s drug

The injection process for subcutaneous Leqembi is expected to take an average of 15 seconds

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links